Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0RMHHV)
| ADC Name |
ABBV-969
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
ABBV-969
Click to Show/Hide
|
|||||
| Organization |
AbbVie (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-PSMA/STEAP1 IgG1 mAb
|
Antibody Info | ||||
| Antigen Name |
Glutamate carboxypeptidase 2 (FOLH1); Metalloreductase STEAP1 (STEAP1)
|
Antigen Info | ||||
| Payload Name |
A-1770637
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
BrAc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
HY-148820
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants must have mCRPC with progression post-NHAs (abiraterone/enzalutamide) and prior taxane therapy, serum testosterone ≤50 ng/dL, measurable disease (RECIST 1.1/PCWG3), PSA ≥1 ng/mL, available tumor tissue, QTc ≤470 msec, and life expectancy >6 months.
|
||||
| Administration Dosage |
Participants will receive escalating doses of ABBV-969.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06318273 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | ||||
| Primary Endpoint |
The study evaluates safety through AE/SAE monitoring (up to 3 years) and efficacy via PSA response (≥50% decrease) in prostate cancer patients, with all events assessed by investigators for treatment relationship.
|
||||
| Other Endpoint |
Secondary endpoints include PK analysis of ABBV-969, and RP2D determination during dose-escalation (up to 2 years) based on safety/PK data.
|
||||
References